In February 2026, the mRNA and cell therapy sectors witnessed a strategic shift toward in vivo applications and more durable RNA constructs. As multinational pharmaceutical companies (MNCs) seek to overcome the logistical hurdles of traditional CAR-T, the spotlight has turned to LNP-mediated delivery and circular RNA (oRNA) platforms.
Below is a breakdown of the key transactions and technical signals from this month.
1. Cell & Gene Therapy: The “In Vivo” Pivot
- Eli Lilly x Orna Therapeutics ($2.4B, Feb 4): Lilly made a massive bet on circular RNA (oRNA) and LNP technology to enter the in vivo CAR-T arena. This deal highlights the industry’s desire to treat autoimmune diseases (like Lupus) by “programming” T-cells directly inside the patient.
- AstraZeneca x AbelZeta ($630M): This collaboration focuses on “armored” CAR-T for solid tumors. While currently ex vivo, the partnership explores next-gen delivery methods to improve T-cell persistence in hostile tumor microenvironments.
2. mRNA Therapeutics: Beyond the Liver
- Moderna x Recordati ($160M, Jan 30/Feb 1): A collaboration centered on mRNA-3927 for propionic acidemia. This underscores the continued expansion of mRNA into rare metabolic diseases and the search for high-purity raw materials for long-term chronic dosing.
- Technical Trend: Extra-Hepatic Targeting: Several mid-stage biotech companies reported progress this month in targeting the lungs and spleen, moving beyond the standard liver accumulation of typical LNPs.
3. Manufacturing & Platform Partnerships
- Sino Biopharmaceutical x Hejia Bio (RMB 1.2B): A full acquisition of an oligonucleotide specialist, reinforcing the importance of advanced delivery platforms and high-yield synthesis for the next generation of RNA drugs.
- Platform Signal: We are seeing a surge in “full-chain” service demands, where biotechs seek partners that provide both the proprietary cap analogs and the LNP formulation under one roof to speed up clinical entry.
Areterna’s Market Perspective:
The “In Vivo” revolution is no longer theoretical—it is being funded by multi-billion dollar deals. However, as the science shifts to complex autoimmune targets, the industry requires higher purity and license-free raw materials to maintain clinical speed and commercial viability.